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In regulation of exposures to hazardous environmental agents, epidemiologic evidence is
especially important in defining human risk estimates. The process of developing appropriate
regulations is complex, however, and depends on many considerations beyond those established
to a high degree of scientific certainty. Thus the needs of regulatory agencies are involved in
the way epidemiologic data are developed and presented. To coordinate and review common
problems associated with preventive and regulatory activities among the federal agencies
concerned with regulation, an Interagency Regulatory Liaison Group (IRLG) was established
in 1977. Because of difficulties encountered by these agencies or Congressional committees in
evaluating epidemiologic evidence, a subcommittee of the IRLG has developed in draft form
guidelines for human population studies to be used in public health decision-making. Although
these guidelines have attracted much controversy, their aim is to present criteria for design and
documentation ofepidemiologic studies, without interfering with the initiative ofinvestigators.
Some aspects of the IRLG guidelines are discussed. The need for epidemiologic research in
providing evidence for regulatory purposes is increasing, but such studies must be well done if
they are to be useful.
In today's society, we are faced with the quan-
dary ofbalancing the risks and benefits ofeconom-
ically useful industrial and commercial products,
which themselves may offer some public health
benefits against the potentially increased risk and
costs of disease in populations exposed to chemi-
cals. The burden of determining such tradeoffs
falls on the shoulders of regulatory agencies, and,
to serve as the foundation for policy decisions,
they hope to have at hand the most thorough and
complete evidence on the health risks of exposure
to environmental contaminants as is possible at a
given point in time. Further, since the goal of
most environmental legislation is, first, to protect
the public health-that is, to protect people-the
best sort of health data for use in policy-making
come from epidemiological studies.
I would prefer to discuss the role that epidemio-
logical research and data play in regulatory
decision-making, and, further, how the special
research and reporting needs of regulatory agen-
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cies should affect the design and conduct of
epidemiologic studies.
Environmental and occupational legislation de-
signed to protect the health and welfare of the
general public and workers has been enacted in
the United States over the last 25 years. This
legislation has focused on cleaning up the envi-
ronment and regulating permissible entry of sub-
stances into the atmosphere, water and food sup-
plies, workplaces and homes. The first Federal law
on air pollution was passed in 1955, and subse-
quently the Clean Air Act of 1963, the intent of
which was to initiate and accelerate a national
research and development program to achieve the
prevention and control of air pollution. Other
environmental acts that were passed throughout
the 1960's and early 70's, such as the Safe Drink-
ing Water Act and Solid Waste Disposal Act,
similarly mandated programs to address pollution
reduction in water and on land.
The primary thrust of the various legislative
acts was, for the pertinent government agency, to
determine the risks-especially the health risks
posed by pollutants or hazardous substances and
then establish safe levels ofexposure, below which
61health should be adequately protected. This, then
indicates how regulatory agencies must view health
research data in order to accomplish their mission.
Regulatory agencies are in the "numbers-setting"
business and, thus, want the data which form the
scientific basis of their regulations and guidelines
to either provide the "numbers" directly or, at
least, be so constructed as to allow development
and estimation of safe levels.
In terms of health data in support of regulation,
data from three types of research approaches are
important. These three sources are: first, toxico-
logical data from studies in animals, and, now,
more and more, in vitro test systems; second,
clinical study data, that is, data derived from
controlled experimental trials in human volun-
teers; and, third, epidemiological data from studies
in human populations. The three approaches are
interrelated and each plays an integral role in risk
assessment and in determining safe levels ofexpo-
sure, bringing their own special data to the pro-
cess. Animal studies are critical, since they can
provide data on high doses and target organs, for
example, and allow development of dose-response
curves. Yet the problem oftranslating animal data
to a human context is likely to remain with us,
even when multiple species information is avail-
able. Clinical studies can be used to verify, under
controlled conditions, estimates derived from field
or population studies, and to develop a dose-
response series in some cases. They are con-
strained, however, by the type ofagent and health
or physiological endpoint under study. Epidemio-
logical studies can provide statistical associations
between agent and health endpoint and can be
weakened by problems with ascertainment of ex-
posure and health endpoint, validity and reliability
of data collection methods, and population enu-
meration, to name a few. Nevertheless, despite
any limitations of the epidemiologic approach, it
still is the most critical for the regulatory process
because it provides information on real people in
real environments. For example, even though
dose-response data may be unattainable, consis-
tently reported effects from various studies in
different populations adds great credence to a
regulatory or policy stance as to whether a hazard
exists or not.
As an aside, I'd like to mention that, in some
cases, data from all three research tools may not
be available to support regulatory actions. But
why regulate if you are not yet confident with the
current body of knowledge? One reason is that
regulatory timetables are frequently prescribed by
legislative mandates. The various amendments to
the Clean Air Act have, for example, required the
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Environmental Protection Agency to propose a
short-term NO2 standard and to reconsider and
revise all the National Air Quality Standards
(NAQS) at least every five years. In terms of
epidemiological studies, suitable populations may
not have been identified or followed for a sufficient
period oftime for the data to be available to add to
regulatory evaluation. Epidemiological studies usu-
ally require relatively long periods of time for
completion, in comparison with animal or mea-
surement studies, yet regulators frequently are
not at leisure to await the results.
Implementation of congressional mandates re-
lated to the environment has been based on the
assumption that sufficient data exist to set and
implement standards concerning unhealthy levels
of exposure to pollutants. Congress has recog-
nized, however, that gaps and deficiencies exist in
the data required for environmental research and
regulatory decisions. The passage of several con-
gressional mandates for improved data and inter-
agency research coordination provides evidence of
this awareness. For example, the Toxic Substances
Control Act of 1976 (P.L. 94-469) specified that
"adequate data should be developed with respect
to the effect of chemical substances and mixtures
on health." One year later, the Clean Air Act
Amendments (P.L. 95-95) established the Task
Force on Environmental Cancer and Heart and
Lung Diseases, whose purpose, in part, was to
"coordinate research and stimulate cooperation
between the Environmental Protection Agency
and the Department of Health, Education, and
Welfare and other involved agencies."
Another example of recognition of the need for
greater regulatory and health research coordina-
tion occurred in 1977, with an important govern-
ment initiative to improve protection of the public
from toxic substances. At that time, four U.S.
agencies which administer laws designed to pro-
tect the public health and safety formed the
Interagency Regulatory Liaison Group -(IRLG).
This interagency was formed in response to Presi-
dent Carter's promise to eliminate waste and
duplication in government. The four agencies are
the Environmental Protection Agency (EPA), the
Consumer Product Safety Commission (CPSC),
the Food and Drug Administration (FDA) and the
Occupational Safety and Health Administration
(OSHA). They established a formal relationship
for cooperation in protecting the public from expo-
sure to harmful levels oftoxic substances by use of
consumer products, foods and drugs, in the
workplace or through exposure to contaminants in
land, air or water. They werejoined in 1978 by the
Food Safety and Quality Service of the Depart-
Environmental Health Perspectivesment of Agriculture. Through the IRLG, these
agencies hope to enhance and coordinate their
preventive and regulatory activities by such means
as developing compatible testing guidelines and
common approaches to the problem of health risk
assessment and by coordinating, when possible,
their research efforts to ensure the best use of
their collective research capability.
One high priority area of mutual concern is the
use of epidemiological research in support of each
agency's regulatory mission. Under the auspices of
the IRLG, an Epidemiology Work Group was
formed which has developed draft documentation
guidelines for population studies used in public
health decision-making.
Some of you may have already seen and re-
viewed these guidelines, since they were circu-
lated to the membership of the Society for Epide-
miological Research and a notice of availability
was published in the Federal Register. A great
number of comments have been received and,
based on these, the draft guidelines are in the
revision forms. Although welcomed by many peo-
ple, the guidelines have stirred up a great deal of
controversy in the epidemiological community; much
of this controversy centers, I believe, on some
misconceptions about the purpose and eventual
use of the guidelines, evidently not made fully
clear in the draft.
Let me first assure you that the intent of these
guidelines is not to pigeonhole or stifle creative
research or scientific exploration. Rather, they
instead reaffirm the IRLG member agencies' com-
mitment to the principles of good, basic epidemio-
logical design in their own research and further,
seek to engage the assistance of the scientific
community in the difficult task of public health
protection by advising researchers of the data and
documentation needs peculiar to the standard
setting process. They do not prescribe research
methods, but rather lay out for policy-makers the
key elements for regulatory decision-making activ-
ities.
These guidelines present the type and extent of
information considered important for both ade-
quate documentation and the objective evaluation
and interpretation of epidemiologic studies. In
addition, they are intended to provide a frame-
work for evaluation by policy-makers, who are not
themselves "epidemiologists. The guidelines will
also provide guidance for those who sponsor and
undertake such studies, the findings of which may
be used in regulatory decision-making. For exam-
ple, instructions for writing grant proposals do not
always lend themselves well to epidemiological
proposals. The guidelines can be used to inform
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potential grantees of the type of information we
would like to see considered in their proposals.
Development of these guidelines arose from a
concern that inadequate documentation or descrip-
tion of evidence needed to evaluate, for example,
the appropriateness of study design, adequacy of
data, and choice ofanalytic methods sometimes led
to conflicting decisions by agencies with related
responsibilities. Continuing debate over the amount
and type of evidence needed to make public health
policy may result in two courses of action: first,
public health actions may be delayed on the
assumption that further research is necessary
before regulatory action can be taken and support-
ed; secondly, unnecessary regulation may be im-
posed because epidemiologic studies are inade-
quately conducted and documented in a way that
serves standard-setting purposes. A variant on
this last point is that legal timetables for regula-
tion must be met despite the absence of well-
developed human data, thus, weakening the set
regulation.
Therefore, the IRLG determined that it is
appropriate and necessary to provide guidelines
for the documentation of epidemiologic studies to
be used in public health decision-making.
Within EPA, we are instituting procedures
which we call "problem-definition" prior to under-
taking an epidemiology study. So that our limited
resources can be put to best use in addressing the
many problems that confront the Agency. Not to
be confused with pilot or feasibility studies, the
problem definition approach established a frame-
work to determine the need for and utility of
undertaking an epidemiology study in a given
population or on a particular agent. The major
areas we want to consider as fully as possible prior
to undertaking a research project are: (1) state-
ment of the problem, including an assessment of
how the data to be derived from such a study could
meet EPA objectives and regulatory and enforce-
ment needs and whether the proposed study would
generate or test hypotheses; (2) a review of the
relevant literature; (3) the projected health and
exposure data needs and likely sources; (4) a
listing of the potential confounding variables; (5)
probable methods of data collection, including
potential biases or limitations; (6) the potential
problems of data access such as confidentiality; (7)
identification and selection issues for study sub-
jects and comparison groups; (8) analytical and
statistical procedures that could be applied and
their attendant biases and limitations; (9) a prelim-
inary assessment of the types of limits that could
be imposed on study inferences and finally (10) a
recommendation of the appropriateness of the
63epidemiological method to address the question at
hand.
I'd like to draw upon both the IRLG Epidemiol-
ogy Documentation Guidelines andproblem-definition
approach to highlight several criteria for planning
and presenting epidemiologic studies that are in-
tended to support regulatory activity:
* Study hypotheses should be biologically plau-
sible
* Any covariates included in the study design
should be biologically plausible
* Studies should be designed to disentangle the
effects of other pollutants or risk factors
* Studies should focus on a clearly defined
health endpoint and enumerate limitations
implicit in the particular data source employed
* Whenever possible, studies should be designed
to quantitate the exposure-disease relation-
ship, incorporating all available information
into a dose-response framework
* Study designs should in most cases be repli-
cable-the study methods must be completely
documented and clearly reported
* Suitable exposed populations and exposure
information must exist to ensure the null
hypothesis can actually be tested.
Because of such problems, I'd like to discuss
these items in greater detail because they are
extremely critical to health evaluation and risk
estimation in regulatory agencies.
One issue that must be dealt with in research
planning is sample size or the statistical power of
any given study to detect excess risk. I believe, in
many cases in the past, inadequate attention has
been paid to statistical power yet regulatory
agencies must frequently make decisions on the
basis of epidemiological data that can be criticized
for looking at two few cases over too short a time.
If resources are adequate and several populations
are available in which chemical agents may be
studied-that is, if choices are available-I be-
lieve power should be an important criterion
applied in planning studies to meet regulatory
research needs and in weighing the merits of
undertaking one study versus another.
This is not to say, however, that if statistical
criteria cannot be met in a given circumstance that
all research should be abandoned. The power of
detection of effects, if present, is an important
design consideration, but the inability to rule out
effects at the low levels characteristic of environ-
mental exposures should not preclude epidemiologic
studies. Much information is to be gained from
well designed research, even if identification of
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safe levels of exposure cannot be accomplished.
This is particularly true when the investigations
are exploratory in nature with little known about
the strength ofthe risk factors and several popula-
tions are available in which chemical agents may
be studied-that is, if choices are available. I
believe power should be an important criterion
applied in planning studies to meet regulatory
research needs and in weighing the merits of
undertaking one study versus another.
This is not to say, however, that if statistical
criteria cannot be met in a given circumstance that
all research should be abandoned. The power of
detection of effects, if present, is an important
design consideration but the inability to rule out
effects at the low levels characteristic of environ-
mental exposures should not preclude epidemiologic
studies. Much information is to be gained from
well designed research even ifidentification ofsafe
levels of exposure cannot be accomplished. This is
particularly true when the investigations are ex-
ploratory in nature with little known about the
strength of the risk factors of concern. This, I
might add, is precisely the problem we are facing
with the relatively recent emergence of toxic
substances as a public health concern. In addition,
the situational nature or problem orientation of
studies and budget requirements often put realis-
tic limits on sample size and prohibit the design of
studies to detect relative risks close to one. In
many cases, a small population is well identified
and characterized as to exposure, also an area of
concern. Adequately sized groups may either be
nonexistent or may lack well defined ties to
exposure data which also weakens the conclusions
that can be drawn. In such circumstances, the
knowledge, especially as to trends and consisten-
cy, to be gained from a series of well designed,
well controlled studies in small, special populations
probably overrides the problem of absolute adher-
ence to sample size criteria.
I raise the issue of power and sample size not
solely in the interest of good design and analysis,
but to emphasize that regulatory agencies must
interpret and evaluate negative as well as positive
studies and want to be able to define safe levels of
exposure with both statistical and technical
confidence. More attention should be devoted to
the constraints of statistical power in the future.
Perhaps we should also place greater emphasis on
two areas: first, on developing innovative approaches
to detecting and analyzing the relatively small
increases in risk likely to be posed by low-level
exposure, and second, on developing biological and
biochemical markers or screening tests for human
subjects to detect preclinical changes and to pre-
Environmental Health Perspectivesdiet and identify high-risk groups. Sole reliance on
disease or mortality outcome, with associated
problems of latency, is often not fully satisfactory
and may not reflect prudent public health policy.
It is desirable for any environmental or occupa-
tional health study to assess as thoroughly as
possible an individual's exposure experience and to
relate this to subsequent health status. Typically,
studies are not undertaken until many years after
the exposure of interest has occurred either be-
cause the factor has just been identified as a
potential risk or clinical disease is just becoming
apparent after the passage of sufficient latency
time. Quantifiable exposure data are usually lack-
ing or difficult to obtain or reconstruct. Efforts
frequently must be made to estimate exposure
qualitatively.
Yet knowing definitively that exposure occurred
and, more importantly, at what level, is of great
concern to regulatory agencies. There is absolutely
no substitute for knowing exposure and how health
outcomes vary as exposure varies. Proposed public
health regulations can rise and fall on this ques-
tion. The importance of the application and devel-
opment of improved exposure assessment tech-
niques in epidemiologic studies cannot be over-
emphasized.
Identification of suitable study populations is an
important element in research planning in regula-
tory agencies. For environmental health research,
in certain instances it is apparent that occupational
groups present the best and sometimes only avail-
able study population for examining risks from
various chemical exposures. Ifno effects are found
at relatively high levels, then concerns about
exposures at much lower environmental levels
may be lessened. It is anticipated that the workplace
environment will continue to be a primary target
for further studies of reproductive hazards to
define the sensitivity of this organ system to
various chemical insults and to test specific hypoth-
eses regarding exposures and adverse reproduc-
tive outcomes.
One area that comes immediately to mind where
a suitable study population is needed is that of
diesel health effects. Because of the widespread
use of diesel engines one might not expect such
difficulty in identifying good study populations.
However, it appears very difficult to fulfill the
major criteria of a stable, long-term group of
sufficient size (probably several thousand) with
substantial exposure that can be estimated from
current measurements. Also, the issue of con-
founding workplace exposures, such as asbestos,
always arises. Knowledge of the obviously critical
variable of smoking habit data is also of concern.
Although numerous suggestions have been made,
a verified study population of diesel exposed sub-
jects is still elusive.
Other populations that may be useful for deter-
mining the health risks posed by exposure to
chemicals are: occupational cohorts and their fami-
lies; consumers of products that may contribute to
domestic and other exposures; school children
attending schools and other groups proximal to
point sources of hazardous chemicals; residents in
areas of heavy industrialization; populations resid-
ing in the vicinity of waste disposal sites; popula-
tions proximal to natural emissions of various
compounds, i.e., hydrocarbons or sulfates.
The final point I would like to make concerns
health endpoints. As we grow more and more
concerned with the potential hazards posed by
chemicals in the environment, studies to deter-
mine effects on the neurological and reproductive
systems assume greater importance. I would like
to add that we should not only be concerned with
pregnancy outcome or sequelae in offspring born
to exposed parents, but we must also address the
effects on reproductive capacity, fertility, miscar-
riages, and abortions in adults.
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